Skip to main content

Advertisement

SpringerLink
Log in

Probiotics and prebiotics for gastrointestinal infections

  • Published:
Current Infectious Disease Reports Aims and scope Submit manuscript

Abstract

There is growing interest in and knowledge about the potential health-promoting benefits of both probiotics and prebiotics. Multiple mechanisms of action for the beneficial effect of probiotics and prebiotics have been postulated, including prevention of pathogenic bacteria growth, production of antimicrobial agents, stimulation of mucosal barrier function, and altering immunoregulation. Clinical trials support the efficacy of probiotics in the treatment of acute infectious diarrhea, the prevention of antibiotic associated diarrhea, and the prevention of recurrent Clostridium difficile infection. Although some data support the potential benefit of probiotic therapy in traveler’s diarrhea, diverticular disease, and Helicobacter pylori, the strength of this evidence is limited. This paper will review the recent literature relevant to the mechanism of action and utility of probiotics and prebiotics in the treatment of gastrointestinal infections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Van Loo JA: Prebiotics promote good health: The basis, the potential, and the emerging evidence. J Clin Gastroenterol 2004, 38(Suppl 2):S70-S75.

    PubMed  Google Scholar 

  2. Backhed F, Ley RE, Sonnenburg JL, et al.: Host-bacterial mutualism in the human intestine. Science 2005, 307:1915–1920. An important publication reviewing how the gut microbiota has coevolved and complements our biology in ways that are mutually beneficial, this paper discusses mechanisms whereby the microbiota operates to maintain the stability and functional adaptability of the gut.

    Article  PubMed  Google Scholar 

  3. Pickard KM, Bremner AR, Gordon JN, et al.: Microbial-gut interactions in health and disease. Immune responses. Best Pract Res Clin Gastroenterol 2004, 18:271–285.

    Article  PubMed  CAS  Google Scholar 

  4. Isolauri E, Salminen S: Probiotics, gut inflammation, and barrier function. Gastroenterol Clin N Am 2005, 34:437–450.

    Article  Google Scholar 

  5. MacDonald TT, Gordon JN: Bacterial regulation of intestinal immune responses. Gastroenterol Clin N Am 2005, 34:401–412. A thoughtful, thorough, and up-to-date review of the interations between the intestinal flora and the mucosal immune system.

    Article  Google Scholar 

  6. Sartor RB: Therapeutic manipulation of the enteric microflora in in.ammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004, 126:1620–1633.

    Article  PubMed  Google Scholar 

  7. Philpott DJ, Giradin SE: The role of toll-like receptors and Nod proteins in bacterial infection. Mol Immunol 2004, 41:1099–1108.

    Article  PubMed  CAS  Google Scholar 

  8. Madsen K, Cornish A, Soper P, et al.: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001, 121:580–591.

    Article  PubMed  CAS  Google Scholar 

  9. Watson JL, McKay DM: The immunophysiological impact of bacterial cpGDNA on the gut. Clin Chim Acta 2005, In press.

  10. Szajewska H, Kotowska M, Mrukowicz JZ, et al.: Efficacy of Lactobacillus GG in prevention of nosocomial diarrhea in infants. J Pediatr 2001, 138:361–365.

    Article  PubMed  CAS  Google Scholar 

  11. Thibault H, Aubert-Jacquin C, Goulet O: Effects of longterm consumption of fermented infant formula with Bi.dobacterim breve and Streptococcus thermophilus on acute diarrhea in healthy infants. J Pediatr Gastroenterol Nutr 2004, 39:147–152.

    Article  PubMed  CAS  Google Scholar 

  12. Choraqui JP, Van Egroo LD, Fichot MC: Acidi.ed milk formula supplemented with Bifidobacterium lactis: Impact on diarrhea in residential care settings. J Pediatr Gastroenterol Nutr 2004, 38:288–292.

    Article  Google Scholar 

  13. Weizman Z, Asli G, Alsheikh A: Effect of a probiotic infant formula on infections in child care centers: Comparison of two probiotic agents. Pediatrics 2005, 115:5–9.

    PubMed  Google Scholar 

  14. Pereg D, Kimhi O, Tirosh A, et al.: The effect of fermented yogurt on the prevention of diarrhea in a healthy adult population. Am J Infect Control 2005, 33:122–125.

    Article  PubMed  Google Scholar 

  15. Allen SJ, Okoko B, Martinez E, et al.: Probiotics for treating infectious diarrhea. Cochrane Database Syst Rev 2004, 2:CD003048. This is a comprehensive and careful review of 23 clinical probiotic trials and provides a balanced assessment of the state of current knowledge in the field.

    PubMed  Google Scholar 

  16. Huang JS, Bousvaros A, Lee JW, et al.: Efficacy of probiotic use in acute diarrhea in children: a meta-analysis. Dig Dis Sci 2002, 47:2625–2634.

    Article  PubMed  CAS  Google Scholar 

  17. Szajewska H, Mrukowicz JZ: Probiotics in the treatment and prevention of acute infectious diarrhea in infants: a systematic review of published randomized, doubleblind, placebo-controlled trials. J Pediatr Gastroenterol Nutr 2001, 33(Suppl 2):S17-S25.

    Article  PubMed  CAS  Google Scholar 

  18. VanNiel CW, Feudtner C, Garrison MM, et al.: Lactobacillus therapy for acute infectious diarrhoea in children: a meta-analysis. Pediatrics 2002, 109:678–684.

    Article  Google Scholar 

  19. Kurugol Z, Koturoglu G: Effects of Saccharomyces boulardii in children with acute diarrhoea. Acta Pediatr 2005, 94:44–47.

    Article  CAS  Google Scholar 

  20. Salazar-Lindo E, Miranda-Langschwanger P, Chea- Woo MC, et al.: Lactobacillus casei strain GG in the treatment of infants with watery diarrhea: A randomized, double-blind, placebo-controlled clinical trial (ISRCTN67363048). BMC Pediatr 2004, 4:18.

    Article  PubMed  Google Scholar 

  21. Costa-Ribeiro H, Ribeiro TC, Mattos AP, et al.: Limitations of probiotic therapy in acute sever dehydrating diarrhea. J Pediatr Gastroenterol Nutr 2003, 36:112–115.

    Article  PubMed  Google Scholar 

  22. Resta-Lenert S, Barrett KE: Live probiotics protect intestinal epithelial cells from infection with enteroinvasive Escherichia coli (EIEC). Gut 2005, 52:988–997.

    Article  Google Scholar 

  23. Paton AW, Jennings MP, Morona R, et al.: Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 2005, 128:1219–1228. This paper provides an interesting glimpse into the potential future role of molecular engineering to design probiotics to perform speci.c anti-infective tasks.

    Article  PubMed  CAS  Google Scholar 

  24. Marteau PR, Vrese Md, Cellier CJ, et al.: Protection from gastrointestinal diseases with the use of probiotics. Am J Clin Nutr 2001, 73(Suppl):430s-436s.

    PubMed  CAS  Google Scholar 

  25. Surawicz CM: Probiotics, antibiotic-associated diarrhea, and Clostridium difficile in humans. Best Pract Res Clin Gastroenterol 2003, 17:775–783.

    Article  PubMed  Google Scholar 

  26. Erdeve O, Tiras U, Dallar Y: The probiotic effect of Saccharomyces boulardii in a pediatric age group. J Trop Pediatrics 2004, 50:234–235.

    Article  Google Scholar 

  27. Kotowska M, Albrecht P, Szajewska H: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea in children: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2005, 21:583–590. This recently published large, randomized, placebo-controlled trial shows the benefit of S. boulardii in the prevention of antibiotic-associated diarrhea in children.

    Article  PubMed  CAS  Google Scholar 

  28. Arvola T, Laiho K, Torkkeli S, et al.: Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: A randomized study. Pediatrics 1999, 104:e64, Available at http://www. pediatrics.org/cgi/content/full/104/5/e64.

    Article  PubMed  CAS  Google Scholar 

  29. Vanderhoof JA, Whitney DB, Antonson DL, et al.: Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children. J Pediatr 1999, 135:564–568.

    Article  PubMed  CAS  Google Scholar 

  30. Cremonini F, Caro SD, Nista EC, et al.: Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhea. Aliment Pharmacol Ther 2002, 16:1461–1467.

    Article  PubMed  CAS  Google Scholar 

  31. D’Souza AL, Rajkumar C, Cooke J, et al.: Probiotics in the prevention of antibiotic associated diarrhea: a metaanalysis. BMJ 2002, 324:1361–1366.

    Article  PubMed  Google Scholar 

  32. Szajewska H, Mrukowicz J: Meta-analysis: non-pathogenic yeast Saccharomyces boulardii in the prevention of antibiotic associated diarrhea. Aliment Pharmacol Ther 2005, 22:365–372. This recent meta-analysis cautiously supports the use of S. boulardii in the prevention of antibiotic associated diarrhea, though recommends further trials.

    Article  PubMed  CAS  Google Scholar 

  33. Pepin J, Valiquette L, Alary ME, et al.: Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466–472.

    PubMed  Google Scholar 

  34. Muto CA, Pokrywka M, Shutt K, et al.: A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273–280.

    Article  PubMed  Google Scholar 

  35. Surawicz CM, McFarland LV, Greenberg RN, et al.: The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000, 31:1012–1017.

    Article  PubMed  CAS  Google Scholar 

  36. Plummer S, Weaver MA, Harris JC, et al.: Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhea. Int Microbiol 2004, 7:59–62.

    PubMed  Google Scholar 

  37. Dendukuri N, Costa V, McGregor M, et al.: Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea. CMAJ 2005, 173:167–170. A recent systematic review of the literature discusses the great variability in the published clinical trials and argues that there is little evidence to strongly support the benefit of S. boulardii in the prevention of C. difficile diarrhea.

    PubMed  Google Scholar 

  38. Kamiji MM, Oliveira RB: Non-antibiotic therapies for Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2005, 17:973–981.

    Article  PubMed  CAS  Google Scholar 

  39. Linsalata M, Russo F, Berloco P, et al.: The influence of Lactobacillus brevis on ornithine decarboxylase activity and polyamine profiles in Helicobacter pylori-infected gastric mucosa. Helicobacter 2004, 9:165–172.

    Article  PubMed  CAS  Google Scholar 

  40. Sheu BS, Wu JJ, Lo CY, et al.: Impact of supplement with Lactobacillus- and Bifidobacterium-containing yogurt on triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002, 16:1669–1675.

    Article  PubMed  Google Scholar 

  41. Sykora J, Valeckova K, Amlerova J, et al.: Effects of a specially designed fermented milk product containing probiotic Lactobacillus casei DN-114 001 on the eradication of H. pylori in children. J Clin Gastroenterol 2005, 39:692–698.

    Article  PubMed  CAS  Google Scholar 

  42. Nista EC, Candelli M, Cremonini F, et al.: Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. Aliment Pharmacol Ther 2004, 20:1181–1188.

    Article  PubMed  CAS  Google Scholar 

  43. Cremonini F, Caro SD, Covino M, et al.: Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: A parallel group, tripleblind, placebo-controlled study. Am J Gastroenterol 2002, 97:2744–2749. The interest in this study lies in its direct comparison of three different probiotics for their effect at preventing side-effects associated with H. pylori therapy. Interestingly, the three probiotic preparations were all equally effective at reducing treatment related symptoms.

    Article  PubMed  Google Scholar 

  44. Armuzzi A, Cremonini F, Bartolozzi F, et al.: Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy: a pilot study. Digestion 2001, 63:1–7.

    Article  PubMed  CAS  Google Scholar 

  45. Myllyuoma E, Veijola L, Ahlroos T, et al.: Probiotic supplementation improves tolerance to Helicobacter pylori eradication therapy—a placebo-controlled double-blind randomized pilto study. Aliment Pharmacol Ther 2005, 21:1263–1272.

    Article  Google Scholar 

  46. Fric P, Zavoral M: The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 2003, 15:313–315.

    Article  PubMed  Google Scholar 

  47. Tursi A, Brandimarte G, Giorgetti GM, et al.: Beclamethasone diproprionate plus VSL#3 for the treatment of mild to moderate diverticular colitis: An open, pilot study. J Clin Gastroenterol 2005, 39:644–645.

    Article  PubMed  Google Scholar 

  48. Salminen MK, Tynkkynen S, Rautelin H, et al.: The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, non-infectious diarrhea in HIV patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study. HIV Clin Trials 2004, 5:183–191.

    Article  PubMed  Google Scholar 

  49. Cunningham-Rundles S, Ahrne S, Bengmark S, et al.: Probiotics and immune response. Am J Gastroenterol 2000, 95(Suppl 1):S22-S25.

    Article  PubMed  CAS  Google Scholar 

  50. Heiser CR, Ernst JA, Barrett JT, et al.: Probiotics, soluble fiber, and L-glutamine (GLN) reduce nelfinavir (NFV)-or lopinavir/ritonavir (LPV/r)-related diarrhea. Int Assoc Physicians AIDS Care (Chic Ill) 2004, 3:121–129.

    Article  Google Scholar 

  51. Hopkins MJ, Macfarlane GT: Nondigestible oligosaccharides enhance bacterial colonization resistance against Clostridium difficile in vitro. Appl Environ Microbiol 2003, 69:1920–1927.

    Article  PubMed  CAS  Google Scholar 

  52. Langlands SJ, Hopkins MJ, Coleman N, et al.: Prebiotic carbohydrates modify mucosa associated microflora of the human large bowel. Gut 2004, 53:1610–1616.

    Article  PubMed  CAS  Google Scholar 

  53. Lewis S, Burmeister S, Cohen S, et al.: Failure of dietary oligofructose to prevent antibiotic-associated diarrhea. Aliment Pharmacol Ther 2005, 21:469–477. This, along with Lewis et al. [54•], is one of two large, placebo-controlled trials by the same group of investigators that came to opposite conclusions regarding the potential of prebiotics to improve outcome in antibiotic-associated diarrhea and C. difficile diarrhea.

    Article  PubMed  CAS  Google Scholar 

  54. Lewis S, Burmeister S, Brazier J: Effect of prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol 2005, 3:442–448. This, along with Lewis et al. [53•], is one of two large, placebocontrolled trials by the same group of investigators that cameto opposite conclusions regarding the potential of prebiotics to improve outcome in antibiotic-associated diarrhea and C. difficile diarrhea.

    Article  PubMed  CAS  Google Scholar 

  55. Rayes N, Seehofer D, Hansen S, et al.: Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: A controlled trial in liver transplant recipients. Transplantation 2002, 74:123–128.

    Article  PubMed  Google Scholar 

  56. Anderson ADG, McNaught CE, Jain PK, et al.: Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut 2004, 53:241–245.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Case Western Reserve University, University Hospitals of Cleveland, 11100 Euclid Avenue, Wearn 247, 44106-5066, Cleveland, OH, USA

    Jeffry A. Katz MD

Authors
  1. Joshua Novak MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffry A. Katz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffry A. Katz MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Novak, J., Katz, J.A. Probiotics and prebiotics for gastrointestinal infections. Curr Infect Dis Rep 8, 103–109 (2006). https://doi.org/10.1007/s11908-006-0005-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11908-006-0005-9

Keywords

Search

Navigation